C, Castaneda L, Gu H, Wong O, Li H, Berman R, Smith C, Albright CF, Dockens R and Arroyo S (2010) The safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of BMS-708163 in young and elderly subjects. Poster presentation at the International Conference on Alzheimer...
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy yo... Background and Objectives Avagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis in cell...
metabolized by CYP2C19) and its active metabolites (e.g., H4), to assess the effects of avagacestat on the pharmacokinetics of carvedilol (metabolized by CYP2C9), and to assess the effects of diltiazem (metabolized by, and a moderate inhibitor of CYP3A4) on the pharmacokinetics of av...
The primary objective of this open-label, nonrandomized, single-sequence study was to assess the effects of BMS-708163 on the pharmacokinetics of CYP-isoform specific probes: midazolam (CYP3A4), S-warfarin (CYP2C9), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) in...